search
Back to results

Belatacept in Kidney Transplantation of Moderately Sensitized Patients (BelatPilot)

Primary Purpose

End Stage Renal Disease, Antibody Mediated Rejection

Status
Withdrawn
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Belatacept
Tacrolimus withdrawal
Plasmapheresis/Intravenous Immunoglobulin G
Thymoglobulin (ATG)
Myfortic
Steroids
Sponsored by
University of Wisconsin, Madison
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for End Stage Renal Disease focused on measuring Renal Transplant, Kidney Transplant, Mean flourescent Intensity, Delayed Graft Function, Antagonist of Thymocyte Cell Activation

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female subjects 18-70 years of age
  • Patient who is receiving an expanded criteria donor (ECD) or deceased cardiac donor (DCD) kidney
  • Have immunodominant donor specific antibodies (DSA) 1,000 - 4,000 mean fluorescent intensity (MFI) by single bead Luminex bioassay
  • Subjects must be capable of understanding the investigational nature and risks of the study and must sign a statement of informed consent
  • Female patients of child bearing potential must have a negative urine or serum pregnancy test within the past 48 hours prior to study inclusion and be willing to use contraceptives for the duration of the study and for 8 weeks after the last dose of study drug Women of Child-Bearing Potential (WOCBP) includes
  • Women who have experienced menarche and who have not undergone successful surgical sterilization or who are not post-menopausal
  • Women using oral contraceptives, other hormonal contraceptives, or mechanical products such as intrauterine devices or barrier methods
  • Women who are practicing abstinence
  • Women who have a partner who is sterile (eg, due to vasectomy).
  • Women must not be breast-feeding
  • Male subjects must agree to use an acceptable method for contraception for the duration of the study
  • Patient must have known positive Epstein-Barr virus (EBV) serostatus

Exclusion Criteria:

  • Patient has previously received an organ transplant other than a kidney.
  • Patient is receiving an human leukocyte antigen (HLA) identical living donor transplant
  • Patient who is a recipient of a multiple organ transplant
  • Patient with a positive T or B cell crossmatch
  • Patient with a donor specific antibody (DSA) as deemed by the local PI to be associated with significant risk of rejection
  • Patient has received an ABO incompatible donor kidney
  • Recipients will be receiving a dual or en bloc kidney transplant
  • Donor anticipated cold ischemia is > 30hours
  • Recipient or donor is known to be seropositive for hepatitis C virus (HCV) or B virus (HBV) except for hepatitis B surface antibody positive. HCV seropositive patients with a negative HCV viral load testing may be included.
  • Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV)
  • Seronegative or unknown EBV serostatus
  • Patient has uncontrolled concomitant infection or any other unstable medical condition that could interfere with the study objectives
  • Patients with tuberculosis who have not been treated for latent infection.
  • Patients at high risk for polyoma virus-associated nephropathy, which is mostly due to BK virus infection
  • Patients at high risk for polyoma virus-associated nephropathy, which is mostly due to BK virus infection
  • Patients with thrombocytopenia (PLT <75,000/mm3), and/or leucopoenia (WBC < 2,000/mm3), or anemia (hemoglobin < 6 g/dL) prior to study inclusion.
  • Patient is taking or has been taking an investigational drug in the 30 days prior to transplant
  • Patient who has undergone desensitization therapy within 6 months prior to transplant
  • Patient has a known hypersensitivity to belatacept, tacrolimus, mycophenolate mofetil, alemtuzumab, rabbit anti-thymocyte globulin, or glucocorticoids
  • Patient is receiving chronic steroid therapy at the time of transplant
  • Patients with a history of cancer (other than non-melanoma skin cell cancers cured by local resection) within the last 5 years
  • Patients with > Grade 2 peripheral neuropathy within 14 days before enrollment
  • Myocardial infarction within 6 months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiography evidence of acute ischemia or active conduction system abnormalities.
  • Female subject is pregnant or breast-feeding
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study. Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness
  • Prisoners or subjects who are involuntarily incarcerated

Sites / Locations

  • University of Wiscsonsin Hospital and Clinics

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Belatacept

Arm Description

Belatacept (nujolix): Tacrolimus withdrawal Standard of care(SOC) treatment: Plasmapheresis/Intravenous Immunoglobulin G (IVIG) therapy Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg starting in the operating room. Maintenance immunosuppression: Myfortic: Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery. Steroids: Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30.

Outcomes

Primary Outcome Measures

Acute rejection
Acute rejection rates are based on assessment of standard of care biopsy (protocol and indication) and standard Banff criteria.

Secondary Outcome Measures

Patient and Graft Survival
The number of subjects alive and with functioning grafts at one year.
Incidence of infections
Number of subjects in the study who have developed infections, including cytomegalovirus (CMV) and BK Virus, in the first year post-transplant
Incidence of de novo donor specific antibody (DSA)
Number of subjects who have developed donor specific antibodies at one year post transplant.
Incidence of new onset diabetes
Number of subjects in the study who have developed new onset diabetes since receiving the transplant
Increase in estimated Glomerular Filtration Rate (eGFR)
Number of subjects in the study whose eGFR has decreased to < 45 milliliters/ minute
Incidence of malignancies
Number of subjects in the study who have developed malignancies including post-transplant lymphoproliferative (PTLD) disorder

Full Information

First Posted
April 30, 2014
Last Updated
December 13, 2018
Sponsor
University of Wisconsin, Madison
Collaborators
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT02130817
Brief Title
Belatacept in Kidney Transplantation of Moderately Sensitized Patients
Acronym
BelatPilot
Official Title
Belatacept for the Management of Moderately Sensitized Patients at Risk for Delayed Graft Function (DGF)
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Withdrawn
Why Stopped
Organ transplant criteria made recruitment difficult. Closed with IRB 10/09/2015.
Study Start Date
September 24, 2014 (Actual)
Primary Completion Date
October 9, 2015 (Actual)
Study Completion Date
October 9, 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Wisconsin, Madison
Collaborators
Bristol-Myers Squibb

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of an immunosuppressive medication, Belatacept, as a replacement for a calcineurin inhibitor, in combination with a standard of care regimen of immunosuppressive medications and plasma exchange (plasmapheresis and immunoglobulin treatment) for kidney transplant patients who are moderately sensitized against their deceased donor and at-risk for delayed graft function. The hypothesis is that moderately sensitized patients who receive Belatacept treatment with the standard of care regimen will lead to lower acute rejection rates than historical controls based on assessment of standard of care biopsies and standard Banff criteria.
Detailed Description
This exploratory single-center, open-label safety and efficacy study will enroll 20 adult kidney transplants candidates, moderately sensitized against their deceased donor and at-risk for delayed graft function (DGF), to receive Belatacept (days 0,5, weeks 2,4,8 and 12 (10 mg/kg), and every 4 weeks thereafter (5 mg/kg)), plasma exchange (once before and twice after transplant) and Intravenous Immunoglobulin (IVIG) (100 mg/kg after each plasma exchange), along with Thymoglobulin (ATG) induction and Dexamethasone tapered dosing starting on the day of transplant at 100mg IV, tapered through Day 4, followed by prednisone at 30 mg on Day 5 with tapered dosing to prednisone 10 mg/d by one month, with a total observation period of 1 year. Patients will be tapered off tacrolimus by week 8 and will remain on mycophenolic acid and prednisone for the total length of the study. Subjects will be followed until 1 year post transplant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End Stage Renal Disease, Antibody Mediated Rejection
Keywords
Renal Transplant, Kidney Transplant, Mean flourescent Intensity, Delayed Graft Function, Antagonist of Thymocyte Cell Activation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Belatacept
Arm Type
Experimental
Arm Description
Belatacept (nujolix): Tacrolimus withdrawal Standard of care(SOC) treatment: Plasmapheresis/Intravenous Immunoglobulin G (IVIG) therapy Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg starting in the operating room. Maintenance immunosuppression: Myfortic: Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery. Steroids: Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30.
Intervention Type
Drug
Intervention Name(s)
Belatacept
Other Intervention Name(s)
Nujolix
Intervention Description
Belatacept will be added to the standard of care regimen and will be given at days 0,5, weeks 2, 4, 8 and 12 (10 mg/kg) and every 4 weeks (5 mg/kg) for one year.
Intervention Type
Drug
Intervention Name(s)
Tacrolimus withdrawal
Intervention Description
Tacrolimus dosing will begin on Days 1 through 5 post transplant at up to 2 mg BID to achieve target trough levels of 9-11 ng/ml. The dose will be tapered through the end of week 2 to achieve a trough level of 4 ng/ml which will be maintained for six weeks. Tacrolimus will be withdrawn at the end of eight weeks post transplant.
Intervention Type
Procedure
Intervention Name(s)
Plasmapheresis/Intravenous Immunoglobulin G
Intervention Description
Enrolled patients will start with standard of practice treatment including plasmapheresis and IVIG therapy twice after transplant, on days 2 and 4 and potentially once before transplant. Plasmapheresis and albumin exchange for one volume of blood will be performed in the infusion center at the University of Wisconsin Hospital and Clinics (UWHC). Each pheresis session will be completed by IVIG infusion. While plasmapheresis will help with the removal of circulating Donor Specific Antibodies (DSA), IVIG therapy will provide immunomodulatory characteristics that include sterilizing immunity from infections, inhibiting and scavenging activated complement fragments, modifying cell-mediated immune responses, inducing regulatory T cells and importantly, inhibiting deleterious antibody production.
Intervention Type
Drug
Intervention Name(s)
Thymoglobulin (ATG)
Other Intervention Name(s)
Anti-thymocyte globulin
Intervention Description
Thymoglobulin (ATG) Induction. Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg via a peripheral or central vein, starting in the operating room.
Intervention Type
Drug
Intervention Name(s)
Myfortic
Intervention Description
Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.
Intervention Type
Drug
Intervention Name(s)
Steroids
Other Intervention Name(s)
Dexamethasone, Prednisone
Intervention Description
Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30.,
Primary Outcome Measure Information:
Title
Acute rejection
Description
Acute rejection rates are based on assessment of standard of care biopsy (protocol and indication) and standard Banff criteria.
Time Frame
one year
Secondary Outcome Measure Information:
Title
Patient and Graft Survival
Description
The number of subjects alive and with functioning grafts at one year.
Time Frame
One year
Title
Incidence of infections
Description
Number of subjects in the study who have developed infections, including cytomegalovirus (CMV) and BK Virus, in the first year post-transplant
Time Frame
One year
Title
Incidence of de novo donor specific antibody (DSA)
Description
Number of subjects who have developed donor specific antibodies at one year post transplant.
Time Frame
One year
Title
Incidence of new onset diabetes
Description
Number of subjects in the study who have developed new onset diabetes since receiving the transplant
Time Frame
One year
Title
Increase in estimated Glomerular Filtration Rate (eGFR)
Description
Number of subjects in the study whose eGFR has decreased to < 45 milliliters/ minute
Time Frame
One year
Title
Incidence of malignancies
Description
Number of subjects in the study who have developed malignancies including post-transplant lymphoproliferative (PTLD) disorder
Time Frame
One year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female subjects 18-70 years of age Patient who is receiving an expanded criteria donor (ECD) or deceased cardiac donor (DCD) kidney Have immunodominant donor specific antibodies (DSA) 1,000 - 4,000 mean fluorescent intensity (MFI) by single bead Luminex bioassay Subjects must be capable of understanding the investigational nature and risks of the study and must sign a statement of informed consent Female patients of child bearing potential must have a negative urine or serum pregnancy test within the past 48 hours prior to study inclusion and be willing to use contraceptives for the duration of the study and for 8 weeks after the last dose of study drug Women of Child-Bearing Potential (WOCBP) includes Women who have experienced menarche and who have not undergone successful surgical sterilization or who are not post-menopausal Women using oral contraceptives, other hormonal contraceptives, or mechanical products such as intrauterine devices or barrier methods Women who are practicing abstinence Women who have a partner who is sterile (eg, due to vasectomy). Women must not be breast-feeding Male subjects must agree to use an acceptable method for contraception for the duration of the study Patient must have known positive Epstein-Barr virus (EBV) serostatus Exclusion Criteria: Patient has previously received an organ transplant other than a kidney. Patient is receiving an human leukocyte antigen (HLA) identical living donor transplant Patient who is a recipient of a multiple organ transplant Patient with a positive T or B cell crossmatch Patient with a donor specific antibody (DSA) as deemed by the local PI to be associated with significant risk of rejection Patient has received an ABO incompatible donor kidney Recipients will be receiving a dual or en bloc kidney transplant Donor anticipated cold ischemia is > 30hours Recipient or donor is known to be seropositive for hepatitis C virus (HCV) or B virus (HBV) except for hepatitis B surface antibody positive. HCV seropositive patients with a negative HCV viral load testing may be included. Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV) Seronegative or unknown EBV serostatus Patient has uncontrolled concomitant infection or any other unstable medical condition that could interfere with the study objectives Patients with tuberculosis who have not been treated for latent infection. Patients at high risk for polyoma virus-associated nephropathy, which is mostly due to BK virus infection Patients at high risk for polyoma virus-associated nephropathy, which is mostly due to BK virus infection Patients with thrombocytopenia (PLT <75,000/mm3), and/or leucopoenia (WBC < 2,000/mm3), or anemia (hemoglobin < 6 g/dL) prior to study inclusion. Patient is taking or has been taking an investigational drug in the 30 days prior to transplant Patient who has undergone desensitization therapy within 6 months prior to transplant Patient has a known hypersensitivity to belatacept, tacrolimus, mycophenolate mofetil, alemtuzumab, rabbit anti-thymocyte globulin, or glucocorticoids Patient is receiving chronic steroid therapy at the time of transplant Patients with a history of cancer (other than non-melanoma skin cell cancers cured by local resection) within the last 5 years Patients with > Grade 2 peripheral neuropathy within 14 days before enrollment Myocardial infarction within 6 months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiography evidence of acute ischemia or active conduction system abnormalities. Female subject is pregnant or breast-feeding Serious medical or psychiatric illness likely to interfere with participation in this clinical study. Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness Prisoners or subjects who are involuntarily incarcerated
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Arjang Djamali, M.D.
Organizational Affiliation
University of Wisconsin, Madison
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Wiscsonsin Hospital and Clinics
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53792
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
19461494
Citation
Trivedi HL, Terasaki PI, Feroz A, Everly MJ, Vanikar AV, Shankar V, Trivedi VB, Kaneku H, Idica AK, Modi PR, Khemchandani SI, Dave SD. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation. 2009 May 27;87(10):1555-61. doi: 10.1097/TP.0b013e3181a4b91b.
Results Reference
background
PubMed Identifier
17699241
Citation
Jordan SC, Pescovitz MD. Presensitization: the problem and its management. Clin J Am Soc Nephrol. 2006 May;1(3):421-32. doi: 10.2215/CJN.01651105. Epub 2006 Apr 12.
Results Reference
background
PubMed Identifier
16426319
Citation
Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant. 2006 Feb;6(2):346-51. doi: 10.1111/j.1600-6143.2005.01178.x.
Results Reference
background
PubMed Identifier
18635429
Citation
Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008 Jul 17;359(3):242-51. doi: 10.1056/NEJMoa0707894.
Results Reference
background
PubMed Identifier
15598320
Citation
Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant. 2004 Dec;8(6):535-42. doi: 10.1111/j.1399-3046.2004.00214.x.
Results Reference
background
PubMed Identifier
18622284
Citation
Magee CC, Felgueiras J, Tinckam K, Malek S, Mah H, Tullius S. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center's experience. Transplantation. 2008 Jul 15;86(1):96-103. doi: 10.1097/TP.0b013e318176ae2c.
Results Reference
background
PubMed Identifier
19155983
Citation
Thielke JJ, West-Thielke PM, Herren HL, Bareato U, Ommert T, Vidanovic V, Campbell-Lee SA, Tzvetanov IG, Sankary HN, Kaplan B, Benedetti E, Oberholzer J. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation. 2009 Jan 27;87(2):268-73. doi: 10.1097/TP.0b013e3181919a16.
Results Reference
background
PubMed Identifier
19584672
Citation
Jordan SC, Toyoda M, Vo AA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation. 2009 Jul 15;88(1):1-6. doi: 10.1097/TP.0b013e3181a9e89a.
Results Reference
background
Citation
Investigator Brochure. Belatacept (BMS-2224818), Version 13. Bristol-Myers Squibb Research and Development Department. 15 December 2010.
Results Reference
background
Citation
U.S. Prescribing information for Nulojix® (belatacept), Revised 06/2011. Bristol-Myers Squibb.
Results Reference
background

Learn more about this trial

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

We'll reach out to this number within 24 hrs